AU2017319218B2 - Modified factor H binding protein - Google Patents

Modified factor H binding protein Download PDF

Info

Publication number
AU2017319218B2
AU2017319218B2 AU2017319218A AU2017319218A AU2017319218B2 AU 2017319218 B2 AU2017319218 B2 AU 2017319218B2 AU 2017319218 A AU2017319218 A AU 2017319218A AU 2017319218 A AU2017319218 A AU 2017319218A AU 2017319218 B2 AU2017319218 B2 AU 2017319218B2
Authority
AU
Australia
Prior art keywords
gly
ala
lys
leu
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017319218A
Other languages
English (en)
Other versions
AU2017319218A2 (en
AU2017319218A1 (en
Inventor
Christoph M TANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Publication of AU2017319218A1 publication Critical patent/AU2017319218A1/en
Publication of AU2017319218A2 publication Critical patent/AU2017319218A2/en
Application granted granted Critical
Publication of AU2017319218B2 publication Critical patent/AU2017319218B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AU2017319218A 2016-08-31 2017-08-31 Modified factor H binding protein Active AU2017319218B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1614687.0 2016-08-31
GBGB1614687.0A GB201614687D0 (en) 2016-08-31 2016-08-31 fHbp scaffold
PCT/GB2017/052535 WO2018042178A1 (en) 2016-08-31 2017-08-31 Modified factor h binding protein

Publications (3)

Publication Number Publication Date
AU2017319218A1 AU2017319218A1 (en) 2019-04-18
AU2017319218A2 AU2017319218A2 (en) 2019-05-02
AU2017319218B2 true AU2017319218B2 (en) 2021-10-28

Family

ID=57119942

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017319218A Active AU2017319218B2 (en) 2016-08-31 2017-08-31 Modified factor H binding protein

Country Status (13)

Country Link
US (1) US12497432B2 (enExample)
EP (1) EP3506934A1 (enExample)
JP (1) JP7525093B2 (enExample)
KR (1) KR102643280B1 (enExample)
CN (1) CN109890412B (enExample)
AU (1) AU2017319218B2 (enExample)
BR (1) BR112019003957A2 (enExample)
CA (1) CA3035159A1 (enExample)
GB (2) GB201614687D0 (enExample)
IL (1) IL265078B2 (enExample)
MX (1) MX420767B (enExample)
WO (1) WO2018042178A1 (enExample)
ZA (1) ZA201901862B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
CN110903400A (zh) * 2019-11-08 2020-03-24 苏州微超生物科技有限公司 B群脑膜炎球菌fHBP多变体融合蛋白及其制备方法与应用
CN111533792B (zh) * 2020-07-07 2020-10-16 康希诺生物股份公司 一种定点突变的载体蛋白及其在制备疫苗中的用途
US20230365979A1 (en) * 2020-09-29 2023-11-16 Idemitsu Kosan Co.,Ltd. Peptide tag and tagged protein including same
IN202321021121A (enExample) * 2023-03-24 2024-04-19

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006024954A2 (en) * 2004-09-01 2006-03-09 Novartis Vaccines And Diagnostics Srl Domains and epitopes of meningococcal protein nmb1870
WO2007060548A2 (en) * 2005-11-25 2007-05-31 Novartis Vaccines And Diagnostics Srl Chimeric, hybrid and tandem polypeptides of meningococcal nmb1870
WO2009114485A2 (en) * 2008-03-10 2009-09-17 Children's Hospital & Research Center At Oakland Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use
WO2011024072A2 (en) * 2009-08-27 2011-03-03 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US7351413B2 (en) * 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
EP2351579B1 (en) * 2002-10-11 2016-09-21 Novartis Vaccines and Diagnostics S.r.l. Polypeptide vaccines for broad protection against hypervirulent meningococcal lineages
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
CA2509484C (en) * 2002-12-10 2012-03-20 Lorantis Ltd. Stabilized immunogenic hbc chimer particles
DK1587537T3 (da) * 2003-01-30 2012-07-16 Novartis Ag Injicerbare vacciner mod multiple meningococ-serogrupper
ES2397923T3 (es) * 2003-10-02 2013-03-12 Novartis Ag Vacunas líquidas para múltiples serogrupos meningocócicos
GB0408977D0 (en) * 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB2414667A (en) * 2004-06-03 2005-12-07 Isis Innovation Vaccine compositions of N. meningitidis PorA and FetA antigens
DE602005025647D1 (de) * 2004-07-23 2011-02-10 Novartis Vaccines & Diagnostic Polypeptide für die oligomerisierung von antigenen
CN101107007B (zh) * 2005-01-27 2011-08-17 奥克兰儿童医院及研究中心 对脑膜炎奈瑟球菌所致疾病具有广谱保护作用的gna1870囊泡疫苗
EP1925318A1 (en) * 2006-11-20 2008-05-28 Paul-Ehrlich-Institut Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu
AU2009215364B2 (en) * 2008-02-21 2014-09-18 Glaxosmithkline Biologicals S.A. Meningococcal fHBP polypeptides
MX2010012999A (es) * 2008-05-30 2012-03-07 U S A As Represented By The Secretary Of The Army On Behalf Of Walter Reed Army Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y uso.
EP2294085A1 (en) * 2008-06-09 2011-03-16 Novartis AG Antibodies against neisserial factor h binding protein
WO2010028096A2 (en) * 2008-09-03 2010-03-11 Children's Hospital & Research Center At Oakland Peptides presenting an epitope of an a domain of factor h binding protein and methods of use
GB0819633D0 (en) * 2008-10-25 2008-12-03 Isis Innovation Composition
CN104548082A (zh) * 2009-03-24 2015-04-29 诺华股份有限公司 为脑膜炎球菌因子h结合蛋白添加佐剂
US9266942B2 (en) * 2009-04-30 2016-02-23 Children's Hospital & Research Center Oakland Chimeric factor H binding proteins (fHbp) and methods of use
CA2779816A1 (en) * 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
EP2544714A1 (en) * 2010-03-10 2013-01-16 GlaxoSmithKline Biologicals S.A. Vaccine composition
TR201802933T4 (tr) * 2010-03-30 2018-03-21 Childrens Hospital & Res Center At Oakland Özellikleri değiştirilmiş faktör h bağlama proteinleri (fhbp) ve bunların kullanım yöntemi.
EP2556085A2 (en) * 2010-04-05 2013-02-13 Bar-Ilan University Protease-activatable pore-forming polypeptides
WO2011161653A1 (en) * 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
KR101584871B1 (ko) * 2010-09-10 2016-01-22 와이어쓰 엘엘씨 네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
WO2013078223A1 (en) * 2011-11-23 2013-05-30 Children's Hospital & Research Center Oakland Anti-factor h binding protein antibodies and methods of use thereof
EP2797624A1 (en) * 2011-12-29 2014-11-05 Novartis AG Adjuvanted combinations of meningococcal factor h binding proteins
WO2013132040A2 (en) * 2012-03-08 2013-09-12 Novartis Ag In vitro potency assay for protein-based meningococcal vaccines
SA115360586B1 (ar) * 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CA2865745C (en) * 2012-03-09 2018-01-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
ES2847923T3 (es) * 2012-06-14 2021-08-04 Glaxosmithkline Biologicals Sa Vacunas contra el meningococo del serogrupo X
GB201215005D0 (en) * 2012-08-23 2012-10-10 Isis Innovation Stabilised meningitis vaccine
CA2903716C (en) * 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
US20160030544A1 (en) * 2013-03-14 2016-02-04 Isis Innovation Limited Immunogenic composition to neisseria
RU2662968C2 (ru) * 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
CN106661092B (zh) * 2014-02-28 2021-07-06 葛兰素史密丝克莱恩生物有限公司 修饰的脑膜炎球菌fHbp多肽
BR112017001417B1 (pt) * 2014-07-23 2023-11-07 Children's Hospital & Research Center At Oakland Variantes da proteína de ligação ao fator h (fhbp), composição imunogênica e uso de uma fhbp variante referência cruzada
EP3223847A1 (en) 2014-11-28 2017-10-04 Janssen Vaccines & Prevention B.V. Meningitis b vaccine
KR20190049940A (ko) * 2015-02-19 2019-05-09 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
SG11201906519RA (en) * 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006024954A2 (en) * 2004-09-01 2006-03-09 Novartis Vaccines And Diagnostics Srl Domains and epitopes of meningococcal protein nmb1870
WO2007060548A2 (en) * 2005-11-25 2007-05-31 Novartis Vaccines And Diagnostics Srl Chimeric, hybrid and tandem polypeptides of meningococcal nmb1870
WO2009114485A2 (en) * 2008-03-10 2009-09-17 Children's Hospital & Research Center At Oakland Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use
WO2011024072A2 (en) * 2009-08-27 2011-03-03 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SCARSELLI MARIA et al: "Rational design of a meningococcal antigen ingucing broad protective immunity". Science Translational Medi, AAAS- American Association for the advancement of Science, US. vol. 3, no. 91, 13 July 2011 *

Also Published As

Publication number Publication date
ZA201901862B (en) 2020-09-30
CN109890412A (zh) 2019-06-14
IL265078A (enExample) 2019-04-30
IL265078B1 (en) 2023-04-01
MX420767B (es) 2025-02-10
JP7525093B2 (ja) 2024-07-30
KR102643280B1 (ko) 2024-03-05
CN109890412B (zh) 2025-04-04
GB201614687D0 (en) 2016-10-12
JP2019526261A (ja) 2019-09-19
GB2568440B (en) 2022-08-17
IL265078B2 (en) 2023-08-01
AU2017319218A2 (en) 2019-05-02
BR112019003957A2 (pt) 2019-06-25
EP3506934A1 (en) 2019-07-10
GB2568440A (en) 2019-05-15
NZ751995A (en) 2024-03-22
WO2018042178A1 (en) 2018-03-08
GB201903866D0 (en) 2019-05-08
US20220112249A1 (en) 2022-04-14
CA3035159A1 (en) 2018-03-08
KR20190064577A (ko) 2019-06-10
AU2017319218A1 (en) 2019-04-18
US12497432B2 (en) 2025-12-16
MX2019002248A (es) 2019-09-18

Similar Documents

Publication Publication Date Title
JP7271654B2 (ja) 改変された髄膜炎菌ｆＨｂｐポリペプチド
JP5676458B2 (ja) 変異ｈ因子結合タンパク質を含むワクチン組成物
US12497432B2 (en) Modified factor H binding protein
EP2861247B1 (en) Vaccines for serogroup x meningococcus
OA19655A (en) Modified factor H binding protein.
US20060141563A1 (en) Mutant protein and refolding method
RU2773464C1 (ru) Модифицированный белок, связывающий фактор н
JP2025518168A (ja) 免疫原性組成物
EA046480B1 (ru) МОДИФИЦИРОВАННЫЕ ПОЛИПЕПТИДЫ МЕНИНГОКОККОВОГО fHbp

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 26 MAR 2019

FGA Letters patent sealed or granted (standard patent)